CNR1 and glioma: In LN18 cells, both formulations upregulated CB1 (2.0–2.6-fold) and CB2 (5.5–5.6-fold), aligning with CB2’s established role in inducing apoptosis and inhibiting glioma proliferation via ceramide accumulation and MAPK suppression [26,28].